

Inventiva invited to present at Stifel 2018 Healthcare Conference in New York and at Jefferies 2018 London Healthcare Conference

Daix (France), October 30, 2018 – Inventiva S.A. ("Inventiva" or the "Company"), a biopharmaceutical company developing innovative therapies in nonalcoholic steatohepatitis (NASH), systemic sclerosis (SSc) and mucopolysaccharidosis (MPS), today announced that Frédéric Cren, Chairman, CEO and co-founder of Inventiva, will present the company and its activities at the upcoming *Stifel 2018 Healthcare Conference*, being held on November 12-14 in New York, USA, as well as at the *Jefferies 2018 London Healthcare Conference*, which will be taking place on November 14-15 in London, UK.

The details of the events are as follows:

Stifel 2018 Healthcare Conference

Date: Tuesday, November 13, 2018 Time: 10:15am (Eastern Time)

Room: Hubbard

Location: Hotel Lotte New York Palace, 455 Madison Ave, New York, USA

<u>Jefferies 2018 London Healthcare Conference</u>

Date: Wednesday, November 14, 2018

Time: 2:40pm (UK time)
Room: Westminster

Location: The Waldorf Hilton, Aldwych, London, UK

The presentation of this last event can be followed simultaneously and in replay at the following address: http://wsw.com/webcast/jeff115/iva/

The presentation document will also be available on the Inventiva website in the "Investor" section

About Inventiva: http://www.inventivapharma.com

Inventiva is a biopharmaceutical company specialized in the development of product candidates interacting with nuclear receptors, transcription factors and epigenetic modulators. Inventiva's research engine has the potential to open up novel therapies against fibrotic diseases, cancers and orphan diseases with substantial unmet medical needs.

Lanifibranor, its lead product, is an anti-fibrotic treatment acting on the alpha, gamma and delta PPARs (peroxisome proliferator-activated receptors), which play key roles in controlling the fibrotic process. Its anti-fibrotic action targets two initial indications with substantial unmet medical need: NASH, a severe and increasingly prevalent liver disease already affecting over 30 million people in the United States, and systemic sclerosis, a disease with a very high mortality rate and for which there is no approved treatment to date.



Inventiva is also developing a second clinical program with odiparcil (IVA 336) for the treatment of patients with mucopolysaccaridosis type VI (or Maroteaux-Lamy syndrome), a rare and severe gene disease affecting children. Odiparcil has also the potential to address other MPS types, characterized by the accumulation of chondroitin or dermatan sulfate (MPS I or Hurler/Sheie syndrome, MPS II or Hunter syndrome, MPS IVa or Morquio syndrome and MPS VII or Sly syndrome). Inventiva is also developing a portfolio of early research projects in the field of oncology.

Inventiva benefits from partnerships with world-leading research entities, such as the Institut Curie in the field of oncology. Two strategic partnerships have also been established with world-class major pharmaceutical companies, AbbVie and Boehringer Ingelheim, in the fields of autoimmune diseases (specifically in psoriasis) and fibrosis, respectively. These partnerships provide milestone payments to Inventiva upon the achievement of preclinical, clinical, regulatory and commercial milestones, in addition to royalties on any approved products resulting from the partnerships.

Inventiva employs over 100 employees and owns R&D facilities near Dijon, acquired from the international pharmaceutical group Abbott. The Company owns, a proprietary chemical library of over 240,000 molecules as well as integrated biology, chemistry, ADME and pharmacology platforms.

Contacts

Inventiva
Frédéric Cren
Chief Executive Officer
info@inventivapharma.com
+ 33 3 80 44 75 00

BrunswickJulien Trosdorf / Yannick Tetzlaff

Media relations inventiva@brunswickgroup.com

+ 33 1 53 96 83 83

LifeSci Advisors

Monique Kosse Investor relations

monique@lifesciadvisors.com

+1 212 915 3820